|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jorge SE, Kobayashi SS and Costa DB:
Epidermal growth factor receptor (EGFR) mutations in lung cancer:
Preclinical and clinical data. Braz J Med Biol Res. 47:929–939.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee
SH, Kim DW, Im SA, Kim TY, Kim CS, et al: Epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for
leptomeningeal metastasis from non-small cell lung cancer patients
with sensitive EGFR mutation or other predictive factors of good
response for EGFR TKI. Lung Cancer. 65:80–84. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Uemura T, Oguri T, Okayama M, Furuta H,
Kanemitsu Y, Takakuwa O, Ohkubo H, Takemura M, Maeno K, Ito Y and
Niimi A: Dramatic intracranial response to osimertinib in a poor
performance status patient with lung adenocarcinoma harboring the
epidermal growth factor receptor T790M mutation: A case report. Mol
Clin Oncol. 6:525–528. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang J, Kim DS and Kim SW: Osimertinib
activity in patients (pts) with leptomeningeal (LM) disease from
non-small cell lung cancer (NSCLC): Updated results from BLOOM, a
phase I study. ASCO Meeting Abs. 34:2016.
|
|
8
|
Grigoriu B, Berghmans T and Meert AP:
Management of EGFR mutated nonsmall cell lung carcinoma patients.
Eur Respir J. 45:1132–1141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gainor JF and Shaw AT: Emerging paradigms
in the development of resistance to tyrosine kinase inhibitors in
lung cancer. J Clin Oncol. 31:3987–3996. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chong CR and Jänne PA: The quest to
overcome resistance to EGFR-targeted therapies in cancer. Nat Med.
19:1389–1400. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cappuzzo F, Varella-Garcia M, Shigematsu
H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V,
Gregorc V, Toschi L, et al: Increased HER2 gene copy number is
associated with response to gefitinib therapy in epidermal growth
factor receptor-positive non-small-cell lung cancer patients. J
Clin Oncol. 23:5007–5018. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim EK, Kim KA, Lee CY and Shim HS: The
frequency and clinical impact of HER2 alterations in lung
adenocarcinoma. PLoS One. 12:e01712802017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hirsch FR, Varella-Garcia M, Bunn PA Jr,
Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C and Franklin WA:
Epidermal growth factor receptor in non-small-cell lung carcinomas:
Correlation between gene copy number and protein expression and
impact on prognosis. J Clin Oncol. 21:3798–3807. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tan D, Deeb G, Wang J, Slocum HK, Winston
J, Wiseman S, Beck A, Sait S, Anderson T, Nwogu C, et al: HER-2/neu
protein expression and gene alteration in stage I–IIIA
non-small-cell lung cancer: A study of 140 cases using a
combination of high throughput tissue microarray,
immunohistochemistry, and fluorescent in situ hybridization. Diagn
Mol Pathol. 12:201–211. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cappuzzo F, Varella-Garcia M, Shigematsu
H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V,
Gregorc V, Toschi L, et al: Increased HER2 gene copy number is
associated with response to gefitinib therapy in epidermal growth
factor receptor-positive non-small-cell lung cancer patients. J
Clin Oncol. 23:5007–5018. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cappuzzo F, Hirsch FR, Rossi E, Bartolini
S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini
I, et al: Epidermal growth factor receptor gene and protein and
gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer
Inst. 97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takano T, Ohe Y, Sakamoto H, Tsuta K,
Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine
I, et al: Epidermal growth factor receptor gene mutations and
increased copy numbers predict gefitinib sensitivity in patients
with recurrent non-small-cell lung cancer. J Clin Oncol.
23:6829–6837. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bell DW, Lynch TJ, Haserlat SM, Harris PL,
Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ,
Iacona RB, et al: Epidermal growth factor receptor mutations and
gene amplification in non-small-cell lung cancer: Molecular
analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol.
23:8081–8092. 2005. View Article : Google Scholar : PubMed/NCBI
|
